Search Results

Baxter to Host Third-Quarter 2021 Financial Results Conference Call for Investors

Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its third-quarter 2021 financial results on Thursday, October 28, 2021 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/3534264 to pre-register for the call and receive the call information.

Baxter Announces U.S. Approval and Launch of Ready-To-Use Cardiovascular Medicine Norepinephrine in Premix Formulation

Baxter International Inc. (NYSE:BAX), a global leader in sterile medication production and delivery, today announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of premix Norepinephrine Bitartrate in 5% Dextrose Injection (norepinephrine). Norepinephrine is indicated to raise blood pressure in adult patients with severe, acute hypotension (low blood pressure).

Baxter to Acquire Hillrom, Expanding Connected Care and Medical Innovation Globally

Baxter International Inc. (NYSE:BAX), a leading global medical products company, and Hillrom (NYSE:HRC), a global medical technology leader, today announced that the companies have entered into a definitive agreement under which Baxter has agreed to acquire Hillrom for $156.00 per share in cash for a total equity value of approximately $10.5 billion and a total enterprise value of approximately $12.4 billion, including the assumption of debt. 

Counselor for Progress

Corporate attorney talks about advancing racial justice at Baxter and lessons learned throughout her career   

Baxter Advances Enterprise Digital Transformation in Collaboration with AWS

Baxter International Inc. (NYSE:BAX), a global medical products company, is accelerating its companywide digital transformation across three strategic areas – developing new digital health solutions to personalize and improve patient care; creating seamless experiences for healthcare customers and patients; and modernizing technology capabilities and business processes to deliver data and insights to employees and customers. The company is working with Amazon Web Services, Inc.

Baxter Announces Acquisition of PerClot Polysaccharide Hemostatic System to Expand Advanced Surgery Portfolio

Baxter International Inc. (NYSE:BAX), a leading global medical products company, announced its Baxter Healthcare Corporation subsidiary has completed the acquisition of certain assets related to PerClot Polysaccharide Hemostatic System from CryoLife, Inc (NYSE:CRY) for up to $60.8 million, including $25 million paid upfront. The remainder will be paid out upon achievement of certain select milestones.

Baxter Reports Second-Quarter 2021 Results

Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the second quarter of 2021. 

Baxter to Present at UBS Genomics 2.0 and MedTech Innovations Summit

Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the UBS Genomics 2.0 and MedTech Innovations Summit on Thursday, August 12, 2021 in Laguna Beach, Calif. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 10:00 a.m. Pacific Time.   The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through August 11, 2022.

Baxter Supports Analysis Demonstrating Clinical and Economic Benefits of Effective Intraoperative Blood Management for Surgical Patients

Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, recognizes the findings of a large retrospective observational analysis published in the Journal of Medical Economics.

Baxter Declares Quarterly Dividend

Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that its Board of Directors has declared a quarterly cash dividend of $0.28 per share of common stock. The dividend is payable on October 1, 2021, to shareholders of record as of September 3, 2021. The indicated annual dividend rate is $1.12 per share of common stock.  About Baxter